Approval Of Patents Will Become Faster But Effective Life Will Not Become Longer

BMI View: Given the abolition of ANVISA's role in the partial evaluation of pharmaceutical patent applications and ongoing investments to accelerate the process for granting intellectual property (IP) protection, BMI believes innovative drugmakers will face fewer hurdles to entering Brazil's domestic patented drug sector. However, deficiencies in the country's IP environment still exist, and judicial decisions in favour of patent challenges filed by domestic generic firms are likely to

To read the full article, please choose one of the following options: